121 related articles for article (PubMed ID: 24950673)
21. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Chapman MJ
Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
[TBL] [Abstract][Full Text] [Related]
22. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
23. Is dyslipidaemia important if we control glycaemia?
Schernthaner G
Atheroscler Suppl; 2005 Sep; 6(3):3-10. PubMed ID: 16055391
[TBL] [Abstract][Full Text] [Related]
24. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations].
Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ
Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358
[TBL] [Abstract][Full Text] [Related]
25. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality.
Barylski M; Toth PP; Nikolic D; Banach M; Rizzo M; Montalto G
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):453-61. PubMed ID: 24840270
[TBL] [Abstract][Full Text] [Related]
26. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
27. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
van de Woestijne AP; van der Graaf Y; Liem AH; Cramer MJ; Westerink J; Visseren FL;
J Am Coll Cardiol; 2013 Nov; 62(20):1834-41. PubMed ID: 23948286
[TBL] [Abstract][Full Text] [Related]
28. Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
Negi S; Ballantyne CM
J Clin Lipidol; 2010; 4(5):365-70. PubMed ID: 21122680
[TBL] [Abstract][Full Text] [Related]
29. HDL-C: does it matter? An update on novel HDL-directed pharmaco-therapeutic strategies.
Gadi R; Amanullah A; Figueredo VM
Int J Cardiol; 2013 Aug; 167(3):646-55. PubMed ID: 22668801
[TBL] [Abstract][Full Text] [Related]
30. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
[TBL] [Abstract][Full Text] [Related]
31. HDL as a target in the treatment of atherosclerotic cardiovascular disease.
Linsel-Nitschke P; Tall AR
Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977
[TBL] [Abstract][Full Text] [Related]
32. Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials.
Deedwania P; Singh V; Davidson MH
Am J Cardiol; 2009 Nov; 104(10 Suppl):3E-9E. PubMed ID: 19895938
[TBL] [Abstract][Full Text] [Related]
33. Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Sampalis JS; Bissonnette S; Habib R; Boukas S;
Ann Pharmacother; 2007 Sep; 41(9):1345-51. PubMed ID: 17666579
[TBL] [Abstract][Full Text] [Related]
34. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
[TBL] [Abstract][Full Text] [Related]
35. [Can cardiovascular events be prevented by raising HDL cholesterol?].
Langslet G; Reikvam A
Tidsskr Nor Laegeforen; 2008 Jun; 128(13):1519-23. PubMed ID: 18587459
[TBL] [Abstract][Full Text] [Related]
36. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
37. Beyond statin therapy: why we need new thinking.
Assmann G
Curr Med Res Opin; 2005; 21 Suppl 6():S3-8. PubMed ID: 16138935
[TBL] [Abstract][Full Text] [Related]
38. High-density lipoprotein and coronary heart disease: current and future therapies.
Natarajan P; Ray KK; Cannon CP
J Am Coll Cardiol; 2010 Mar; 55(13):1283-99. PubMed ID: 20338488
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Karlson BW; Barter PJ; Palmer MK; Lundman P; Nicholls SJ
Nutr Metab Cardiovasc Dis; 2012 Sep; 22(9):697-703. PubMed ID: 22705128
[TBL] [Abstract][Full Text] [Related]
40. [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?].
Badimón JJ; Santos-Gallego CG; Badimón L
Rev Esp Cardiol; 2010 Jun; 63 Suppl 2():20-35. PubMed ID: 20540898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
